Encapsulating peritoneal sclerosis (EPS) is an occasional and serious complication for peritoneal dialysis (PD) patients for whom no evidence-based management strategies have yet been established. Encapsulating peritoneal sclerosis could appear after kidney transplantation in patients who previously underwent long-term PD. In this report, we present our experience in four PD patients diagnosed with EPS after kidney transplantation. Adhesiolysis provided improvement in their acute clinical conditions and allograft functions, despite the long-term follow-up. Surgical intervention may be a safe modality for this specific group of patients.
Introduction
Encapsulating peritoneal sclerosis (EPS) is an occasional and serious complication for peritoneal dialysis (PD) patients (1) . The incidence varies between 0.7-7.5% among patients still on PD therapy. Exposure to hypertonic glucosecontaining solutions, a long duration of PD therapy and increased number of peritonitis episodes play contributing roles in its development (2) ; however, the exact etiopathogenetic mechanisms are unclear. Animal models have shown that macrophages and fibroblasts lead to damage in the mesothelial cells via the secretion of various cytokines, such as transforming growth factor (TGF)-β1 and vascular endothelial growth factor (VEGF) (3) . Inflammation, neovascularization and fibrosis ultimately result in calcification and sclerosis in the peritoneal membrane (4) . Encapsulating peritoneal sclerosis has a latent nature causing ultrafiltration failure, intermittent symptoms of bowel obstruction and occasionally ascites in affected patients. Furthermore, the longterm follow-up mortality rate is high (5) .
Encapsulating peritoneal sclerosis may also develop in renal transplanted patients who previously underwent PD therapy. In this specific group of patients, the incidence ranges between 1-3% (6). Additionally, there are currently no evidence-based management strategies for post-transplant EPS cases. In this report, we present our experience of four PD patients diagnosed with EPS after kidney transplantation who underwent surgical interventions which provided clinical improvements and functional allografts in their long-term follow-up. tinuous ambulatory PD therapy and receiving four daily manual exchanges with 2,000 cc solutions containing dextrose and icodextrin as osmotic agents. The dextrose concentrations of the standard solutions were prescribed according to the patients' volume statuses. Icodextrin was prescribed for night-time hours and remained in the peritoneal space for at least 8 hours. The calcium concentrations were prescribed according to the patients' needs. None of the patients had previously used biocompatible solutions. The total number of peritonitis episodes in each patient was 3, 4, 2 and 1, respectively. The latest data regarding their peritoneal transport statuses and dialysis adequacy are presented in Table. Three of the patients had cadaveric and one had livingunrelated kidney transplantation and triple immunosuppressive therapy was started. Peritoneal dialysis catheters were removed in the first month of transplantation without any complication. The patients were put on follow-up in our nephrology and transplantation clinic. During the posttransplantation period, the patients attended regular outpatient visits and complained of intermittent gastrointestinal complaints, including decreases in appetite (cases 1-3) and nausea (case 4). However, they did not complain of insistent symptoms or weight losses, suggesting EPS up to the last 3 months. All of the patients had a previous history of medication usage other than accompanying diseases and immunosuppressive agents. Hospitalizations were required due to poor dietary intake (cases 1-4), nausea (cases 1-4), vomiting (cases 2 and 3), abdominal pain (cases 1-4) and renal dysfunction (cases 1-4). On clinical examination, all of the patients exhibited ileus signs and had weight losses of 8, 6, 8 and 9 kg, respectively. Drug toxicity, infections, and postrenal conditions likely to cause acute abdominal syndrome were evaluated. Abdominal computed tomography scans without contrast agent revealed peritoneal thickening (cases 1-4), peritoneal enhancement (cases 2 and 3), peritoneal calcifications (cases 1-4), adhesions of bowel loops (cases 1-4) and fluid loculation (cases 2 and 3). According to the clinical and radiologic findings, the diagnosis of EPS was confirmed for all cases. Their oral intakes were stopped, na-sogastric tubes were inserted, and parenteral nutrition and intravenous fluid resuscitations were initiated. The patients were already on low-dose corticosteroid treatment and their prednisolone dosages were increased to 40 mg per day. Cases 1 and 2 were put on low-dose ramipril therapy. The clinical picture of ileus refractory to medical treatment was indicative for surgery in all patients. Laparotomy showed a thin membrane over the peritoneum (cases 1-4), peritoneal thickening (cases 1-4), peritoneal calcification (cases 1-4) and multiple fibrous bands between the intestinal loops (cases 1-4). Adhesiolysis was subsequently performed. After surgery, the clinical symptoms regressed in all patients within one week. Oral feeding was gradually introduced. None of the patients exhibited gastrointestinal system associated complaints and gained weight within weeks. The prednisolone doses were tapered to 5 mg per day in 8 weeks, while the other immunosuppressive agents were maintained at the previously prescribed doses.
The present cases are still under follow-up with functional grafts in their 87th, 38th, 76th and 88th months of transplantation, respectively (Table) .
Discussion
The long duration of PD therapy, increased number of peritonitis episodes, and usage of either hypertonic dextrose or icodextrin solutions are established risk factors for the development of EPS (2, 7). However, EPS is a dynamic process in which fibrosis and neovascularization are maintained even after the triggering agent has been removed (8) . Thus, EPS may appear in kidney transplanted patients who previously underwent PD. A recent study showed that kidney transplantation itself and the usage of calcineurin inhibitors as part of immunosuppressive regimens also increased the risk of EPS (7). The fact is that, for whatever reason, there are currently no evidence-based approaches for posttransplant EPS cases and the currently available data have been limited to case reports in the medical literature.
For the post-transplant cases, we initially planned a supportive approach to relieve the ileus symptoms and to restore the nutrition and hydration following the diagnosis of EPS. At the same time, several medical approaches were attempted to alleviate the ongoing histopathological alterations in accordance with the relevant data. Our cases were already on 5 mg per day prednisolone treatment as part of their immunosuppressive regimens. Because these agents have antiinflammatory properties, the reduced doses of corticosteroids in recent maintenance immunosuppressive regimens have been suggested as contributing factors to the increased number of post-transplant cases (9) . Hence, we increased the prednisolone doses to 40 mg per day with the intent of tapering the dose. Case 1 received everolimus therapy at the time of diagnosis. Indeed, the available data showed favorable outcomes with mammalian target of rapamycin inhibitors due to their inhibitory effects on neoangiogenesis through VEGF blockage (10). Cases 2-4 received tacrolimus therapy, which was initiated at the beginning of the immunosuppression therapy. There are conflicting reports regarding the use of calcineurin inhibitors, which could aggravate the expression of TGF-β and may have contributed to the progression of peritoneal pathology (11) . The last three patients were also receiving mycophenolate sodium. In a previous report, the combination of corticosteroids with mycophenolate mofetil treatment has been shown to be effective in EPS cases receiving PD therapy (12) . Hence, we did not change the immunosuppressive regimens in our cases (except a transient increase in the prednisolone dosage) due to the anti-inflammatory effects of corticosteroids, antiproliferative effects of everolimus and the positive clinical outcomes with low-dose calcineurin inhibitors (13) and mycophenolate mofetil (12) . On the other hand, reninangiotensin-aldosterone system inhibitors have been suggested to slow down the progression of peritoneal sclerosis via their inhibitory effects on the expression of TGF-β1 and fibronectin in human peritoneal mesothelial cells (14) . Therefore, we prescribed low doses of ramipril for all cases; however, cases 3 and 4 failed to tolerate ramipril due to hypotensive episodes.
In patients with EPS refractory to conservative treatment strategies, surgery is an alternative approach, which includes adhesiolysis and enterolysis. However, there are also conflicting results in the medical literature regarding this issue. In a large case series from Japan, the authors revealed that 181 out of 239 patients responded to adhesiolysis with no complications in their long-term follow-up (15) , whereas, in another case series, the authors reported no response with decapsulation and partial deserosation in 45 EPS patients, among whom three cases died (16) . Regarding surgical interventions, the data are even more limited in the setting of post-transplant cases. Gökçe et al. reported a favorable outcome with adhesiolysis in one of their two post-transplant EPS cases (17) . Basi ! et al. presented a post-transplant EPS case who experienced an improved clinical course after adhesiolysis, but lost her allograft (18) . Other groups reported good responses with combinations of surgery plus tamoxifen therapy (19) and everolimus/low-dose calcineurin inhibitor (13) .
In the present cases, the clinical conditions worsened within a few weeks despite the supportive approaches. After surgical intervention, we observed improvements in their clinical pictures and oral feedings. Surgery also provided restoration of the renal functions to baseline levels. None of the patients have developed recurrent EPS symptoms in the long-term follow-up. Although kidney transplantation itself increases the risk for EPS development, the prognosis of post-transplant cases is better compared to non-transplant cases. A recent study demonstrated lower median C-reactive protein levels in post-transplant cases compared to that of non-transplant cases. The authors concluded that immunosuppressive therapy alleviated inflammation in these cases (20) . We also observed decreased C-reactive protein levels after surgery in our cases. We speculate that main-tained immunosuppressive therapy may have contributed to favorable outcomes in our patients in the short-and longterm follow-up.
In conclusion, it should be kept in mind that EPS has an insidious nature and the overt clinical signs could appear even after kidney transplantation. Clinical suspicion is important in patients who underwent particularly long-term PD therapy, resulting in the risk of EPS development. Surgical intervention may be a safe treatment modality for posttransplant EPS cases. Further investigations with larger cohorts are necessary to confirm our findings.
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